Zacks Investment Research on MSN3d
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug
Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing ...
CNET16d
GLP-1 Meds Like Ozempic: Know Potential Benefits, Risk Factors and Overdose Info
Dr. Mensen adds that tirzepatide (Mounjaro or Zepbound), a dual GLP-1/GIP agonist, may also be recommended. "Based on the fact that each individual experience with this medication is different ...
Nasdaq17d
How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma
It is developing VK2735, an investigational novel dual GLP-1 and GIP receptor agonist, in different clinical studies as oral and SC versions for treating obesity. Per the terms, CordenPharma will ...
Pharmabiz18d
Viking Therapeutics inks broad manufacturing pact with CordenPharma to support commercialization of VK2735
VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, is being developed in both oral and subcutaneous ...
MarketWatch18d
Viking Therapeutics’ new contract is a game changer. Here’s how much money it could bring in.
to support the commercialization of its oral obesity drug VK2735. The deal covers supply of both the active pharmaceutical ingredient, or API, and the final finished product. Back To Top ...